Quick Highlights of Pre-Market Gainers: NASDAQ:OXGN, NASDAQ:DXCM, NASDAQ:NURO, NYSE:AEO

New York, NY -- (SBWIRE) -- 11/07/2013 -- OXiGENE Inc. (NASDAQ:OXGN) is a clinical-stage, biopharmaceutical company developing novel therapeutics primarily to treat cancer. The Company primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, and also are associated with visual impairment in a number of ophthalmological diseases and conditions. OXiGENE Inc. is currently trading at $3.84 up 7.26% in pre-market on 14560 shares traded. OXGN's RSI is currently at 73.28 which indicates that the stock is overbought.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.